Hakin-1 / University of A Coruña - LARVOL DELTA

E3 ubiquitin-ligase Hakai regulates LRP4 stability and Wnt/β-catenin signalling in colorectal cancer cells. (PubMed, iScience) - "Pharmacological inhibition of Hakai with Hakin-1, a selective inhibitor of its HYB domain responsible for E3 ubiquitin-ligase activity, reduced tumoursphere formation and promoted differentiation-associated features. Furthermore, these findings highlight Hakai inhibition as a potential CSC-directed therapeutic strategy in colorectal cancer."

Journal • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • LRP4

Targeting protein degradation as a novel cancer therapeutic strategy: from research to innovation (EACR 2022) - "Moreover, Hakin-1 inhibits tumour growth in xenografted mice This represents an important step forward in further development of an effective therapeutic drug that would prevent or inhibit carcinoma tumour progression. Conclusion As Hakin-1 exerts an antitumor activity in colon cancer cells, by inhibiting proliferation, colony formation, migration and invasion, accompanied by an elevation of E-cadherin expression at cell-cell contacts, we will discuss the potential of the project to advance into a novel therapeutic strategies to halt cancer."

Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • CDH1